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Summary 
The human immunodeficiency virus (HIV-1) infects T lymphocytes via an interaction between 
the virus envelope  glycoprotein gp120 and the CD4 antigen of T  helper cells. Previous studies 
demonstrated that mutations in various regions of CD4 domain 1 lead to the loss of gp120 binding. 
In the present study the gp120 binding site was constructed in rat CD4 by replacing rat with 
human CD4  sequence.  A  series of mutants was constructed the best of which bound gp120 
with an affinity only twofold less than that of human CD4. The data indicate that the gp120 
binding site of human CD4 is constituted by residues  33-58  of domain 1. 
C 
D4 on T  lymphocytes is the target for infection with 
HIV-1  (1) via binding of the viral glycoprotein gpl20 
(2).  CD4 contains four Ig-related domains with domain 1 
resembling the variable  domain of an Ig light chain (3, 4). 
Domain 1 of CD4 is sufficient for high-affinity binding of 
gp120 (5, 6), and mutation experiments resulting in the loss 
of gp120 binding have been undertaken in an attempt to map 
the gp120 binding site. The most informative studies are those 
where single amino acids were changed and initially CD4 
residues 42-49 were suggested to encompass the gp120 site 
(7). Another study identified a similar region but also raised 
the possibility that sequence  in domain 2 is important for 
gp120  binding (8).  Later studies showed that mutation at 
residue 55 destroyed gp120 binding (6) and that mutations 
outside the 42-55 region also affected binding, namely mu- 
tations at residues  58, 59, 67, and 68 in one study (9),  and 
at residues 29, 59-64, 77-81, and 85 in another (10). In con- 
sidering these data and the three-dimensional structure (11, 
12), Kyu et al.  (11) focused on the region 41-59  as being 
important for gp120 binding, with changes at residues  77, 
81,  and 85  also requiring consideration. 
To complement the negative mutation data, we have con- 
structed a gp120 binding site in rat CD4 by replacing rat 
with human CD4  sequence. 
Materials and Methods 
Mutagenesis of  Rat CD4.  Rat CD4 cDNA (4) was subcloned 
as a BamHI fragment into MDmp19 for mutagenesis using a com- 
mercial kit (Amersham International, Amersharn, Bucks, UK). To 
introduce human CD4 sequences as shown in Fig. 1 C, oligonucleo- 
fide sequences  were taken from the human CD4 cDNA sequence (3) 
and flanked with 12 bases of the rat CD4 sequence to ensure cor- 
rect binding of the oligonucleotides to the template. The mutants 
were sequenced and the Ball fragment containing the coding se- 
quence of mutants 2-5 was subcloned into the expression vector 
CDM8 (13, 14). Alternatively,  PCR was used to generate  constructs 
encoding soluble forms of the mutants  as described (15). 
Immunofluorescence Analysis  of gp120  and  Antibody  Binding. 
Mouse mAbs and gpl20: mAb OX65 reacts with domains 3 and 
4 of  rat CD4 (unpublished  data), and mAbs 6.3G4 and 7.3Fll bind 
domain 1 of human CD4 (16). mAb 108 is directed against gpl20 
(D. Healey,  unpublished data). The gpl20 of HTLV-III3B  type was 
expressed in Chinese hamster ovary (CHO) cells and supplied by 
the MKC AIDS Directed Programme (London, UK). COS cells 
(4.5  x  106) were transfected with the CDM8 vectors as described 
(13, 14) and analyzed  for gp120 or antibody binding by fluorescence- 
activated cell sorting  (17). 
Inhibition  of  12SI-labeled human  Soluble (s)CD4 Binding  to 
gp120.  50 #1 of  rabbit anti-mouse (RAM) IgG antibody at 50 #g/ 
ml was added to the wells of a Falcon 3911 plate (Becton Dick- 
inson and Co., Oxnard, CA) and left for 1 h at room temperature. 
The wells were blocked with 0.5% BSA, washed, and then 50 #1 
of anti-gpl20 mAb 108 (tissue culture supernatant) was added to 
the wells for incubation overnight at 4~  The plates were washed 
and 100 #1 of  CHO cell  tissue  culture supernatant  containing soluble 
gp120 at 300 ng/ml was added to each well for incubation at 4~ 
for 5 h.  After washing the plates 20 #1 of 300-320 ng/ml 12sI 
human sCD4 (10-15 #Ci/#g) was added to each well in the pres- 
ence of serial dilutions in PBS, 2% BSA of  unlabeled  human sCD4, 
rat sCD4, or fivefold-concentrated  tissue culture supernatants from 
CHO cells expressing the various soluble mutants. After overnight 
incubation at 40C, the plates were washed and the radioactivity 
bound was measured by gamma counting. 
Inhibition of  1-1abeled  Human sCD4 Binding to mAb 6.3G4. 
The assay was as for binding to gp120 except that the anti-CD4 
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Figure 1.  (A) Models for human and rat CD4. Glycosylation  sites are shown (  [  ). (B) The structure of CD4 domain 1 as in references 11 and 
12. The failed region shows the segment of mutant 6 that is identical  to human CD4. (C) Human and rat CD4 sequences (3, 4) in domains  1 and 
2 that were exchanged in the mutants are underlined,  with/~ strands assigned as in references 11 and 12. The dots under the rat sequence mark identical 
residues in the two species. 
mAb 6.3G4 was bound to RAM IgG antibody on the plate and 
the mI human sCD4 was added at 160-200 ng/ml. 
Results  and Discu.ion 
Models for human and rat CD4 are shown in Fig.  1 A. 
The levd of sequence identity between the two species is 54% 
in the extracellular part and 50% in domain 1. A model for 
CD4 domain 1 is shown in Fig. 1 B with the re#on encom- 
passed by mutant 6, which gave the best binding to gpl20, 
shown in black.  The sequences in the regions of mutation 
are shown in Fig.  1  C. 
Mutant  1 containing human residues 36-51 incorporates 
the region first proposed for the gpl20  site (7).  In mutant 
2 this region was extended to residue 62 on the basis of the 
study by Arthos et al.  (6)  and this mutant was then used 
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Figure 2.  Binding of antibodies  and gp120 to rat,  human, and mutant rat CD4. COS cells were transiently  transfected with CDM8 containing 
(13, 14) the genes for rat, human, and mutant CD4, and then analyzed by fluorescence-activated cell sorting.  (~p) Heavy lines represent cells incubated 
with the anti-rat CD4 mAb OX65, ~cept for cells expressing human CD4 that were labeled with the anti-human CD4 mAb 7.31=11 (16). Dotted 
lines represent  cells incubated  with a control mAb, OX21,  that recognizes human complement C3b inactivator.  (M/rid/e) Heavy lines show labeling 
of ceils with the 6.3G4 anti-human CD4 mAb (16); dotted lines represent results with the mAb OX21. (Bottom) Heavy lines represent cells incubated 
with gp120 before incubation  with the anti-gp120  mAb 108; dotted lines represent  cells incubated  with the anti-gp120  mAb 108 only. 
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Figure 3.  Mutant  CD4 inhibition of lzsI human  sCD4 binding  to 
gp120 (A) or the mAb 6.3G4 (B). The wells of a plate coated with RAM 
were incubated successively  with the anti-gpl20 mAb 108 and then recom- 
binant soluble HIV-1 gp120, or with the mAb 6.3G4 alone. The binding 
of lzSI-labeled human sCD4 to gp120 or the mAb was measured in the 
presence of serial dilutions  of either human sCD4 (hsCD4),  rat sCD4 
(rsCD4),  or soluble forms of the various mutants.  The counts shown are 
the averages of triplicate  assays and are from representative  experiments. 
as the basis for the subsequent  mutants. In mutant 3 the 
N-glycosylation site in domain 2 of rat CD4 was removed 
from mutant 2, and in mutant 4 changes in the region of 
domain 2 postulated to be important in gp120 binding (8) 
were added. Mutant 5 incorporates the two changes in mu- 
tants 3 and 4. In mutants 6-9 mutant 2 was extended to Gln- 
33, shortened to Arg-59 or to Arg-58, or mutated at posi- 
tion 80 from Gln to Asp, respectively. 
In initial experiments gp120 did not bind to HeLa cells 
expressing mutant 1. Mutants 2-5 were therefore prepared 
and transiently expressed in COS cells. Expression was de- 
tected for rat CD4 and mutated CD4 by labeling with the 
OX65 mAb that binds the COOH-terminal half of rat CD4 
(unpublished data) and for human CD4 by labeling with the 
anti-human CD4 mAb 7.3Fll  (16) (Fig. 2).  In addition, 
human CD4 and the mutants were labeled with the 6.3G4 
mAb that reacts with CD4 domain 1 (16). The binding of 
gp120 from HIV-1 was seen with human but not rat CD4, 
and mutants 2-4 were also clearly labeled with gp120. Mu- 
tant 5 was negative for gp120 binding, even  though the 6.3G4 
mAb bound to mutant 5. 
These data indicated that the changes made in mutant 2 
were sufficient to generate a gp120 binding site in rat CD4. 
The additional changes in mutants 3 and 4 appeared to have 
no effect, although these mutants were not characterized fur- 
ther. To determine the affinity of mutant 2 for gp120, the 
protein was expressed in a soluble form (15) and used in an 
inhibition assay in which the binding of 12si human sCD4 
to immobilized gp120 was measured. This assay avoids any 
possibility of multivalent interactions. Fig. 3 A shows repre- 
sentative data indicating that both human sCD4 and mutant 
2 inhibit the binding of t2sI human sCD4.  From eight de- 
terminations,  the relative affinity of mutant 2 for gp120 was 
determined to be 60-70-fold less than that of human CD4. 
It is known that changes in one amino acid can lead to a 
complete loss of gp120 binding (reviewed in references 11 
and 12) and therefore it seems likely that the region encom- 
passing residues 36-62 is central to the binding site for gp120. 
However, the binding site for gp120 was not fully con- 
stituted by residues 36-62, and therefore additional mutants 
were constructed. Inspection  of the x-ray crystallographic 
structure of human CD4 suggested that nonconservative sub- 
stitutions present in mutant 2 at the C, C' turn could affect 
the binding site. Specifically,  I1e-34 and Lys-35 are substituted 
by Lys and Thr residues, respectively (Fig. 1). Therefore, in 
mutant 6 the humanized region was extended back to the 
conserved Gln at position  33 and this mutant was shown 
to have an affinity for gp120 only twofold less than that of 
human CD4 (Fig. 3 A). This indicates that the C, C' turn 
has a key role in forming the binding site for gp120, but it 
is not yet clear which of the two substitutions  is responsible 
for the improved binding. In other studies, Ile-34 has been 
mutated to Arg (6, 8) and Lys-35 mutated to Glu (7) and 
Ala (10) but these mutations had little or no effect on gp120 
binding. The present study suggests that some substitutions 
in this region cannot be tolerated.  The Lys at position 34 
might specifically  interfere with hydrophobic packing or Thr 
at position 35 might form inappropriate hydrogen bonds in 
mutant 2 that disrupt the C', C" loop. 
In mutants 7 and 8, rat CD4 residues were restored at po- 
sitions 60-61 and 59-61. This was done because inspection 
of the CD4 structure indicated that the side chains of the 
human CD4 residues Arg-59/Ser-60/Leu-61 point away from 
the C', C" loop and thus these residues might not be essen- 
tial for binding.  Moreover, mutagenesis  experiments  have 
shown that Ser-60 can be mutated to Arg (7, 9) or Ala (10), 
and Leu-61 mutated to Arg (9) without disrupting gp120 
binding, and that the substitution of Arg-59 with Gly (9) 
or Ala (10) only partially  disrupts  binding. Mutant 7 was 
marginally better at inhibiting gp120 binding than mutant 
2, and mutant 8, with the addition of the Lys-59/Arg inter- 
change, reproducibly bound gp120 with a three-fold-higher 
affinity than mutant 2 (Fig. 3 A). Studies with the 6.3G4 
antibody (Fig. 3 B) showed that changes in this region can 
affect binding reactions since mutant 8 with the Arg-59/Lys 
interchange binds about 40 times less well to the 6.3G4 anti- 
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antibody binding data argue against residues 59-61 being cen- 
trally involved in the gp120 binding site but Arg-59 could 
be on the periphery of the site. 
Mutant 9 was made because mutation analysis of human 
CD4 had suggested the involvement of amino acids 77-81 
(10) in gp120 binding and because residue 80 differs between 
rat and human CD4. The rat Gin residue was mutated to 
Asp in mutant 9, but this had only a small beneficial effect 
on the binding of gp120  (Fig.  3 A). 
In conclusion, these experiments strongly indicate that the 
gp120 binding site of human CD4 is constituted by residues 
33-58 and highlights the importance of the C, C' turn in 
forming the binding site. In previous studies  residues  out- 
side this region have been mutated to disrupt gp120 binding, 
but the data presented here argue against the possibility that 
these regions are part of the binding site. 
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